Meeting
2021 ASCO Annual Meeting
Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC).
Authors
Cheryl D. Cho-Phan
Flatiron Health, San Francisco, CA
Cheryl D. Cho-Phan , Jeremy Snider , Liangliang Zhang , Kimberly McGregor , Alexa Betzig Schrock , Emily Castellanos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1036)
DOI
10.1200/JCO.2021.39.15_suppl.1036
Abstract #
1036
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
First Author: Rinath Jeselsohn
Poster
2023 ASCO Annual Meeting
Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.
First Author: Jin Juan
Poster
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
First Author: Joshua Z. Drago
Poster
2023 ASCO Annual Meeting
Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).
First Author: Qianyu Yuan